Roohvand Farzin, Shokri Mehdi, Abdollahpour-Alitappeh Meghdad, Ehsani Parastoo
a Department of Virology , Pasteur Institute of Iran , Pasteur Ave, Tehran , Iran.
b Department of Immunology , Pasteur Institute of Iran , Tehran , Iran.
Expert Opin Ther Pat. 2017 Aug;27(8):929-951. doi: 10.1080/13543776.2017.1339789. Epub 2017 Jun 22.
Yeasts, as Eukaryotes, offer unique features for ease of growth and genetic manipulation possibilities, making it an exceptional microbial host. Areas covered: This review provides general and patent-oriented insights into production of biopharmaceuticals by yeasts. Patents, wherever possible, were correlated to the original or review articles. The review describes applications of major GRAS (generally regarded as safe) yeasts for the production of therapeutic proteins and subunit vaccines; additionally, immunomodulatory properties of yeast cell wall components were reviewed for use of whole yeast cells as a new vaccine platform. The second part of the review will discuss yeast- humanization strategies and innovative applications. Expert opinion: Biomedical applications of yeasts were initiated by utilization of Saccharomyces cerevisiae, for production of leavened (fermented) products, and advanced to serve to produce biopharmaceuticals. Higher biomass production and expression/secretion yields, more similarity of glycosylation patterns to mammals and possibility of host-improvement strategies through application of synthetic biology might enhance selection of Pichia pastoris (instead of S. cerevisiae) as a host for production of biopharmaceutical in future. Immunomodulatory properties of yeast cell wall β-glucans and possibility of intracellular expression of heterologous pathogen/tumor antigens in yeast cells have expanded their application as a new platform, 'Whole Yeast Vaccines'.
酵母作为真核生物,具有易于生长和便于进行基因操作的独特特性,使其成为一种出色的微生物宿主。涵盖领域:本综述提供了关于酵母生产生物制药的一般性见解和面向专利的见解。只要有可能,专利都与原始文章或综述文章相关联。该综述描述了主要的公认安全(GRAS)酵母在生产治疗性蛋白质和亚单位疫苗方面的应用;此外,还综述了酵母细胞壁成分的免疫调节特性,以探讨将完整酵母细胞用作新型疫苗平台的可能性。综述的第二部分将讨论酵母人源化策略和创新应用。专家观点:酵母的生物医学应用始于利用酿酒酵母生产发酵产品,之后发展到用于生产生物制药。更高的生物量产量、表达/分泌产量、糖基化模式与哺乳动物的更高相似度以及通过应用合成生物学进行宿主改良策略的可能性,可能会增加未来选择巴斯德毕赤酵母(而非酿酒酵母)作为生产生物制药宿主的几率。酵母细胞壁β-葡聚糖的免疫调节特性以及在酵母细胞内异源病原体/肿瘤抗原的细胞内表达可能性,已扩大了其作为新型平台“全酵母疫苗”的应用。